




# *In vivo* evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome

Daniel Todt

Department of Molecular and Medical Virology  
Faculty of Medicine - Institute of Hygiene and Microbiology



## Increasing prevalence of Hepatitis E virus



most common cause of acute viral hepatitis

- > 3 million symptomatic cases p.a.
- about 70,000 deaths p.a.



Wehmeyer et al., Z Gastroenterol. 2018




## EUROPE'S NEW HEPATITIS PROBLEM

Many get infected with hepatitis E, and a few get very sick. How can the virus be stopped?

By Kai Kupferschmidt Science, 2016


## Increasing prevalence of Hepatitis E virus



- almost 420,000 new infections – most of them unnoticed
- ca. 3,000 severe HEV infections
- 1:1,250 blood products HEV RNA positive


Faber et al., *Journal of Viral Hepatitis*. 2017

## Worldwide distribution of hepatitis E virus



Nimgaonkar et al., *Nat Rev Gastroenterol Hepatol.* 2018

# Course of infection of Hepatitis E




SVR



Capai et al., Viruses 2018


treatment failure

# Ribavirin – Modes of action




Todt et al., *Viruses* 2016

## Sequencing of viral populations




adopted from Lauring et al. *PLoS Pathogens* 2010

## Sequencing of viral populations




Domingo et al., *Microbiol and Mol. Biol Reviews* 2012

## Selected patients for our study




Todt & Gisa et al., Gut 2016

## Number of sites exhibiting variations in the HEV ORF1 region without the influence of RBV




Todt & Gisa et al., Gut 2016

## RBV increases the heterogeneity of the viral intra-host population





Todt & Gisa et al., Gut 2016

## A *in vivo* identified SNV confers increase in fitness




Todt &amp; Gisa et al., Gut 2016

## A *in vivo* identified SNV confers increase in fitness



Todt & Gisa et al., Gut 2016

## Summary



Todt et al., *Curr Opinion Virol* 2018

## Outlook





ELSEVIER

Contents lists available at ScienceDirect


## Antiviral Research

journal homepage: [www.elsevier.com/locate/antiviral](http://www.elsevier.com/locate/antiviral)

## The natural compound silvestrol inhibits hepatitis E virus (HEV) replication *in vitro* and *in vivo*



Daniel Todt<sup>a,b,1</sup>, Nora Moeller<sup>b,1</sup>, Dimas Praditya<sup>b</sup>, Volker Kinast<sup>b</sup>, Martina Friesland<sup>b</sup>, Michael Engelmann<sup>b</sup>, Lieven Verhoye<sup>c</sup>, Ibrahim M. Sayed<sup>c,d</sup>, Patrick Behrendt<sup>b,e</sup>, Viet Loan Dao Thi<sup>f,g</sup>, Philip Meuleman<sup>c</sup>, Eike Steinmann<sup>a,b,\*</sup>





ELSEVIER

Contents lists available at ScienceDirect



## Antiviral Research

journal homepage: [www.elsevier.com/locate/antiviral](http://www.elsevier.com/locate/antiviral)

## The natural compound silvestrol inhibits hepatitis E virus (HEV) replication *in vitro* and *in vivo*



Daniel Todt<sup>a,b,1</sup>, Nora Moeller<sup>b,1</sup>, Dimas Praditya<sup>b</sup>, Volker Kinast<sup>b</sup>, Martina Friesland<sup>b</sup>, Michael Engelmann<sup>b</sup>, Lieven Verhoye<sup>c</sup>, Ibrahim M. Sayed<sup>c,d</sup>, Patrick Behrendt<sup>b,e</sup>, Viet Loan Dao Thi<sup>f,g</sup>, Philip Meuleman<sup>c</sup>, Eike Steinmann<sup>a,b,\*</sup>



## Acknowledgement

Project with a nomination by ICPerMed "Best Practice in Personalised Medicine" Award 2018



### Institute of Experimental Virology

Eike Steinmann

Patrick Behrendt

Richard J.P. Brown

Thomas Pietschmann

ROBERT KOCH INSTITUT



### Department of Infectious Diseases

C. Thomas Bock

Aleksandar Radonic

Andreas Nitsche



Bundesministerium  
für Bildung  
und Forschung

### Department of Gastroenterology, Hepatology and Endocrinology

Anett Gisa

Heiner Wedemeyer

Birgit Bremer

Pothakamuri Venkata Suneetha

Sven Pischke

Michael P. Manns

Markus Cornberg